Literature DB >> 7286035

A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tablet.

W H Aellig, H H Narjes, E Nüesch, R J Oertle, J E Devos, W Pacha.   

Abstract

In 10 healthy volunteers the time course of cardiac beta-adrenoceptor blocking activity, plasma levels and cumulative urinary excretion of pindolol were compared during a 4-day course of pindolol 5 mg (Visken) t. d. s., and one tablet of pindolol 20 mg retard (Visken retard) once a day. After oral administration of the 20 mg retard tablet, plasma concentrations of pindolol higher than half the maximum value (1/2 Cp (tmax)) were maintained about 2.5 times as long as after administration of the conventional 5 mg tablet. This is evidence for an important and marked retardation of drug release. During treatment with pindolol 20 mg retard once daily, cardiac beta-adrenoceptor blockade, measured by the reduction in exercise-induced tachycardia and in the exercise-induced rise in systolic blood pressure, at almost all times throughout the 24 h period was at least as great as during treatment with pindolol 5 mg t. d. s. This suggests that patients successfully treated with pindolol 5 mg t. d. s. can be maintained with the same beta-adrenoceptor blockade by a single tablet of pindolol 20 mg retard once daily.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7286035     DOI: 10.1007/BF00544595

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  [Clinicopharmacological studies with pindolol following intravenous and oral administration].

Authors:  W H Aellig
Journal:  Adv Clin Pharmacol       Date:  1976

2.  Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.

Authors:  J Meier; E Nüesch
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Initiation of once-daily pindolol treatment.

Authors:  G Frithz
Journal:  Br Med J       Date:  1978-02-04

4.  Beta-adrenoceptor-blocking agents: pharmacokinetic differences and their clinical implications illustrated on pindolol.

Authors:  J Meier
Journal:  Cardiology       Date:  1979       Impact factor: 1.869

5.  Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets.

Authors:  W H Aellig; E Nüesch; W Pacha
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  [The practice of hypertensive therapy using a beta receptor blocker. A multicentric study using 15 mg Visken].

Authors:  J Rosenthal; H Kaiser; D Hammerschmidt; D Welzel
Journal:  Med Welt       Date:  1977-12-02

7.  Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris.

Authors:  B F Robinson
Journal:  Circulation       Date:  1967-06       Impact factor: 29.690

8.  [Beta-blockader, pindolol, in the therapy of angina pectoris; a report on a multicentric controlled study].

Authors:  E Lang; P Fitscha; W Schiess
Journal:  Wien Med Wochenschr       Date:  1979-09-30

9.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

10.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

View more
  5 in total

1.  Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?

Authors:  W M Blankesteijn; S J Graafsma; M P Hectors; E A Olde Riekerink; J F Rodrigues de Miranda; T Thien
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.

Authors:  Y Yamada; K Matsuyama; K Ito; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

3.  Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.

Authors:  R Lapka; T Sechser; V Rejholec; M Peterková; M Votavová
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers.

Authors:  Marleen Wingen; Kim P C Kuypers; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2006-11-24       Impact factor: 4.530

5.  Comparison of the effect of pindolol and propranolol on heart rate after acute and chronic administration.

Authors:  M B Finch; P C O'Connor; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.